Enliven Therapeutics (ELVN) Projected to Post Earnings on Wednesday

Enliven Therapeutics (NASDAQ:ELVN) is expected to be releasing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Enliven Therapeutics to post earnings of ($0.44) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06). On average, analysts expect Enliven Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock opened at $41.58 on Wednesday. The company’s fifty day simple moving average is $36.54 and its 200-day simple moving average is $27.06. The stock has a market capitalization of $2.53 billion, a PE ratio of -22.35 and a beta of 0.32. Enliven Therapeutics has a 1-year low of $14.78 and a 1-year high of $48.53.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ELVN. HC Wainwright lifted their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Mizuho lifted their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. Finally, Wall Street Zen cut shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.40.

Insider Activity at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 5,000 shares of Enliven Therapeutics stock in a transaction on Friday, February 6th. The shares were sold at an average price of $29.04, for a total transaction of $145,200.00. Following the transaction, the insider owned 740,188 shares in the company, valued at approximately $21,495,059.52. The trade was a 0.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Benjamin Hohl sold 10,000 shares of Enliven Therapeutics stock in a transaction on Friday, March 6th. The shares were sold at an average price of $29.58, for a total transaction of $295,800.00. Following the transaction, the chief financial officer owned 51,000 shares in the company, valued at approximately $1,508,580. This trade represents a 16.39% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 16,230 shares of company stock worth $473,201. 25.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Commodore Capital LP lifted its stake in shares of Enliven Therapeutics by 0.4% during the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock valued at $94,138,000 after buying an additional 17,809 shares in the last quarter. Vestal Point Capital LP increased its holdings in Enliven Therapeutics by 230.2% in the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after acquiring an additional 2,670,000 shares during the last quarter. Polar Capital Holdings Plc increased its holdings in Enliven Therapeutics by 1.5% in the 3rd quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock valued at $63,355,000 after acquiring an additional 44,713 shares during the last quarter. Vanguard Group Inc. increased its holdings in Enliven Therapeutics by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock valued at $52,260,000 after acquiring an additional 142,378 shares during the last quarter. Finally, State Street Corp increased its holdings in Enliven Therapeutics by 9.1% in the 4th quarter. State Street Corp now owns 1,052,862 shares of the company’s stock valued at $16,214,000 after acquiring an additional 87,725 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.